0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Expedited Review of New Drugs

Emily Jane Woo, MD, MPH
JAMA. 2013;309(3):236-237. doi:10.1001/jama.2012.56911.
Text Size: A A A
Published online

Extract

To the Editor: Mr Moore and Dr Furberg1 stated that “the US Senate, in approving a regular 5-year update to the Food, Drug, and Cosmetic Act, proposed a further expansion of expedited review, with a new category for ‘breakthrough drugs.’” They also expressed concerns about “ . . . complex safety issues raised by the expedited approval pathway.” The US Food and Drug Administration (FDA) Amendments Act of 2007 expanded the agency's authority regarding drug safety. Under this act, the FDA may require a risk evaluation and mitigation strategy to manage a known or potential serious risk associated with a drug or biological product,2 as well as a postmarketing requirement at the time of product approval, or after approval, if the FDA becomes aware of new safety information.3 Postmarketing studies may be required to assess a known serious risk related to the use of the product, to assess signals of serious risk related to the use of the product, or to identify an unexpected serious risk when available data indicate the potential for a serious risk.3 Comprehensive safety evaluations are performed 18 months after approval of a new drug or biological product.4 Since 2008, biweekly screening of the FDA Adverse Event Reporting System has identified 210 potential signals of serious risks or new safety information.5 In their discussion of safety concerns associated with dabigatran, Moore and Furberg neglected to point out that 2 of these potential signals pertain to that drug.5

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

January 16, 2013
Thomas J. Moore, AB; Curt D. Furberg, MD, PhD
JAMA. 2013;309(3):236-237. doi:10.1001/jama.2012.56920.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();